Patient engagement in drug development is a vital part of patient-centered drug development, and its value and implementation have been recognized and actively explored by leading countries or regions in the field of medicine all over the world. Since November 2021, the Center for Drug Evaluation has issued six guidelines or drafts for patient-centered drug development. Patients provide suggestions and feedback in time through deep participating in the drug development, while collecting and analyzing the information require scientific research methods to ensure the quality of patient data and the rigor and transparency of reports. Qualitative or mixed-methods research is a scientific research method suitable for patients open information collection, analysis, and reporting. However, these two methods may not be widely recognized in the field of drug development. Therefore, this paper briefly introduces these two methods and their application in patient involvement in drug development, aiming to improve the quality of related research.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |